Laura Tatiana Picón Moncada

Laura Tatiana Picón Moncada

Auto-generated profile, based on publicly available information

Laura Tatiana Picón Moncada

Cancer and Molecular Medicine Research Group (CAMMO), Bogotá D.C., Colombia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2024 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
JBJheremy Sebastian Reyes Barreto
Jheremy Sebastian Reyes Barreto
LJLeidy Viviana Giron Jurado
Leidy Viviana Giron Jurado
MEMaria Paula Montoya Estrada
Maria Paula Montoya Estrada
IMIris Lorena Sánchez Moreno
Iris Lorena Sánchez Moreno
LMLaura Tatiana Picón Moncada
Laura Tatiana Picón Moncada
LFLibia Adriana Gaona Fernández
Libia Adriana Gaona Fernández
Multiple Myeloma (MM) is the second most common hematological malignancy and one of the 19 most frequent types of cancer. Its diagnosis is a challenge due to the low rate of disease recognition, and diagnosis delays lead to the characteristic end-organ damage of the disease. New approaches to tackle that diagnosis challenge are required. Emerging evidence shows that Piwi-interacting RNAs (piRNA) promote increased methylation in MM cells. In this analysis, we delve into the latest discoveries surrounding piRNA biogenesis and functions, offering fresh perspectives on the possible uses of piRNAs in detection and diagnosis in MM. piRNA-823 increases in MM cells and positively correlates with the disease stage. Its tumorigenic actions in MM relate to intercellular communication between MM and vein endothelial cells. These findings provide the necessary information to highlight the possible role of piRNA-823 as a biomarker for MM diagnosis.

10 December 2025 in Biomédica
Verified
Journal Article
Open access
PDF file
JRJheremy Sebastián Reyes
Jheremy Sebastián Reyes
JGJhonathan David Guevara
Jhonathan David Guevara
LPLaura Tatiana Picón
Laura Tatiana Picón
ISIris Lorena Sánchez
Iris Lorena Sánchez
LGLibia Andrea Gaona
Libia Andrea Gaona
LPLuis Eduardo Pino
Luis Eduardo Pino
Introduction. PIWI-interacting RNAs are small and non-coding RNAs involved in gene regulation and transposable element repression, emerging as critical biomarkers and therapeutic targets in oncology. Advances in artificial intelligence, such as recurrent neural networks, long short-term memory networks, and graph convolutional networks, offer significant improvements in PIWI-interacting RNA detection.Objectives. To evaluate the performance of artificial intelligence models, including recurrent neural networks, long short-term memory, and graph convolutional networks, in detecting PIWI-interacting RNAs and assessing their implications for cancer diagnostics and prognosis.Materials and methods. A systematic review of 24 studies was conducted across PubMed, ScienceDirect, Scopus, and Web of Science, focusing on artificial intelligence-based approaches for PIWI-interacting RNA detection. Inclusion criteria were original articles published in English or Spanish using artificial intelligence models in clinical or experimental settings. Performance metrics such as accuracy, sensitivity, and specificity were analyzed.Results. Long short-term memory models achieved the highest overall accuracy (92.3%), followed by graph convolutional networks (91.4%), support vector machines (88%), and recurrent neural networks (85.7%). Sensitivity and specificity were also highest in long short-term memory (94% and 91%, respectively). Graph convolutional networks showed superior performance in identifying PIWI-interacting RNA-disease associations with complex datasets. Support vector machine models were effective in smaller datasets but exhibited scalability limitations.Conclusion. Artificial intelligence models, especially long short-term memory and graph convolutional networks, significantly enhance PIWI-interacting RNA detection, supporting their application in cancer diagnostics and personalized medicine. Future studies should refine these models, address dataset biases, and explore their integration into clinical workflows.

9 August 2024 in Hematology & Transfusion International Journal
Verified
Journal Article
Open access
PDF file
JRJheremy S Reyes
Jheremy S Reyes
JRJheremy E Reyes
Jheremy E Reyes
LPLaura T Picón
Laura T Picón
MBMaría Alejandra Rodríguez Brilla
María Alejandra Rodríguez Brilla
Introduction: This systematic review synthesizes current evidence on the role of PIWI-interacting RNAs (piRNAs) in leukemia and lymphoma, emphasizing their potential as diagnostic markers and therapeutic targets. Leukemia and lymphoma represent significant challenges in oncology, warranting exploration of novel biomarkers beyond conventional methods. piRNAs, a class of small non-coding RNAs, exhibit dysregulated expression in tumor tissues and biological fluids, suggesting their utility in disease diagnosis and targeted therapy. Methods: A systematic search was conducted in PubMed and ScienceDirect databases following PRISMA guidelines. Eligible studies explored piRNA expression, diagnostic efficacy in leukemia and lymphoma tissues, and therapeutic implications. Included studies spanned from 2000 to 2024 and underwent rigorous quality assessment. Results: Initially identifying 26 papers, the review included 5 studies meeting inclusion criteria. These studies identified specific piRNAs, such as piR-32877 and piR-30473, with significant diagnostic potential in leukemia and lymphoma (AUC = 0.78). Insights from extracellular vesicle-derived piRNAs, like piR-36225, suggested promising applications for disease monitoring (AUC = 0.69). Conclusions: piRNAs emerge as promising biomarkers for non-invasive diagnosis and therapeutic targets in leukemia and lymphoma. Future research should validate these findings across diverse populations and elucidate underlying mechanisms to advance clinical utility.

3 September 2025 in Revista Colombiana de Ortopedia y Traumatología
Verified
Journal Article
Open access
PDF file
MBMaría Alejandra Rodríguez Brilla
María Alejandra Rodríguez Brilla
JRJheremy Sebastian Reyes
Jheremy Sebastian Reyes
LPLaura Tatiana Picón
Laura Tatiana Picón
JCJuan Fernando Cortes
Juan Fernando Cortes
Introduction: Bone metastases (BM) are a major complication in patients with advanced cancer, resulting in pain, fractures, and other skeletal-related events (SREs) that greatly affect quality of life. Objective: To provide an updated overview of the current management strategies for BM. Methodology: This systematic review adhered to the PRISMA 2020 guidelines and was registered in PROSPERO (CRD42024586182). A comprehensive literature search was performed in July 2024 across PubMed, ScienceDirect, and Scopus, using terms related to BM and Boolean operators (OR, AND, and NOT). The search strategy was refined to only include studies published since January 2020. Randomized controlled trials (RCTs), clinical trials (CTs), and cohort and case-control studies published in English or Spanish assessing various management strategies for BM, such as surgery, radiotherapy, systemic therapies, and supportive care, and reporting data on the outcomes of interest were included. The Newcastle-Ottawa Scale was used for quality assessment. Results: A total of 131 records were retrieved from the searches. After duplicate removal and title and abstract and full-text screening, 27 studies were included in the review: 13 RCTs, 7 CTs, 6 cohort studies, and 1 case-control study with an aggregate sample of 14 672 patients. Radiotherapy, particularly multifractionated regimens and stereotactic body radiotherapy, was shown to improve pain relief and bone stability. Systemic therapies, including immune checkpoint inhibitors and bone-targeted agents, demonstrated efficacy in reducing skeletal-related events. Emerging techniques such as percutaneous vertebroplasty combined with ablative methods demonstrate potential in minimizing complications and improving quality of life. Conclusion: The management of BM continues to evolve, with personalized, multimodal approaches being essential for achieving optimal outcomes. Further research should focus on enhancing predictive models, exploring novel therapies, and integrating bone-targeted agents to reduce complications and improve both survival and quality of life in patients with bone metastases.

27 June 2025 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
JBJheremy Sebastian Reyes Barreto
Jheremy Sebastian Reyes Barreto
LMLaura Tatiana Picón Moncada
Laura Tatiana Picón Moncada
IMIris Lorena Sánchez Moreno
Iris Lorena Sánchez Moreno
LFLibia Adriana Gaona Fernández
Libia Adriana Gaona Fernández
Introduction: This systematic review explores the roles of PIWI-interacting RNAs (piRNAs) and PIWI-like proteins in pancreatic cancer, assessing their potential as diagnostic and therapeutic biomarkers. Recent studies suggest that piRNAs and PIWI proteins play roles in gene regulation associated with cancer progression, positioning them as promising targets in oncology. Methods: The review adhered to PRISMA guidelines, focusing on the potential of piRNAs and PIWI-like proteins as biomarkers for diagnosis, prognosis, or therapeutic prediction in pancreatic cancer. Studies in PubMed, EMBASE, and ScienceDirect were included, focusing on expression data, diagnosis, prognosis, or treatment of pancreatic tumors. Only studies published in English or Spanish from the last five years were considered. Risk of bias was assessed using SYRCLE’s tool, a modified CONSORT checklist, and AMSTAR2. Results: Five key studies were selected. Findings indicate that piR-162725 enhances diagnostic accuracy for early-stage pancreatic cancer in combination with CA19-9, while piR-017061 inhibits pancreatic cancer cell growth through EFNA5 mRNA degradation. PIWIL1 promotes metastasis via a piRNA-independent pathway, and piR-hsa-30937 in small extracellular vesicles creates an immunosuppressive environment in pancreatic neuroendocrine tumors. Conclusions: piRNAs and PIWI-like proteins demonstrate potential as biomarkers and therapeutic targets in pancreatic cancer. Future studies are required to validate these findings in larger cohorts and explore piRNA-based therapies. An in-depth understanding of piRNAs' mechanistic roles could improve early detection and therapeutic outcomes in pancreatic cancer.

1 April 2025 in Acta Neurológica Colombiana
Verified
Journal Article
Open access
PDF file
JBJheremy Sebastian Reyes Barreto
Jheremy Sebastian Reyes Barreto
JPJuan Sebastian Aguirre Patiño
Juan Sebastian Aguirre Patiño
LMLaura Tatiana Picón Moncada
Laura Tatiana Picón Moncada
RVRaul F. Vega-Alvear
Raul F. Vega-Alvear
Introduction: Neurodegenerative disorders (NDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), and tauopathies are highly prevalent and cause significant public health concerns globally. Although research has focused on pathological proteins such as ?-amyloid, the growing interest in non-coding RNAs, including piRNAs, is shifting the understanding of neurodegenerative disorder mechanisms. Objective: This review aims to summarize the evidence of the role of piRNAs in neurodegenerative disorder pathogenesis and their potential as diagnostic biomarkers. Materials and methods: A systematic review was conducted following PRISMA guidelines. We included randomized controlled trials, cohort studies, and case-control studies focusing on piRNAs in neurodegenerative disorders. Data were extracted from PubMed and ScienceDirect using search terms related to piRNAs and neurodegenerative diseases published between 2009 and 2024. Results: Eleven studies met the inclusion criteria. These studies highlighted the dysregulation of piRNAs in diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, suggesting that piRNAs influence disease mechanisms by maintaining genomic stability, regulating transposable elements, and participating in protein degradation. Several piRNAs, including piR-hsa-92056, emerged as potential biomarkers with diagnostic accuracy. Discussion: The evidence underscores the crucial role of piRNAs in neurodegeneration. Mechanistic studies reveal that piRNA dysfunction may trigger cascades of genomic instability leading to neuronal death. piRNAs are emerging as valuable therapeutic targets and biomarkers in neurodegenerative disorders. Conclusions: piRNAs hold potential as innovative therapeutic and diagnostic tools in NDs. Future research should focus on developing piRNA-based interventions to prevent neurodegeneration.